An overview of current treatment strategies for β-thalassemia

Bibliography

• Weatherall DJ. The inherited diseases of hemoglobin are an emerging global health burden. Blood 2010;115(22):4331-6
   PubMed Web of Science ®Google Scholar
• Colah R, Gorakshakar A, Nadkarni A. Global burden, distribution and prevention of beta-thalassemias and hemoglobin E disorders. Expert Rev Hematol 2010;3(1):103-17
   PubMed Web of Science ®Google Scholar
• Modell B, Darlison M. Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ 2008;86(6):480-7
   PubMed Web of Science ®Google Scholar
• Thein SL. The molecular basis of beta-thalassemia. Cold Spring Harb Perspect Med 2013;3(5):a011700
   PubMed Web of Science ®Google Scholar
• Weatherall DJ, Clegg JB. The thalassaemia syndromes. Blackwell Science, Oxford; 2001
   Google Scholar
• Guidelines for the management of non transfusion dependent thalassaemia (NTDT). Thalassaemia International Federation. 2013. Available from: http://www.thalassaemia.org.cy/wp-content/uploads/pdf/educational-programmes/Publications/Non-Transfusion%20Dependent%20Thalassaemias%20%282013%29/NTDT%20ENGLISH.pdf
   Google Scholar
• Fucharoen S, Weatherall DJ. The hemoglobin E thalassemias. Cold Spring Harb Perspect Med 2012;2(8):a011734
   PubMed Web of Science ®Google Scholar
• Cazzola M, Finch CA. Evaluation of erythroid marrow function in anemic patients. Haematologica 1987;72(3):195-200
   PubMed Web of Science ®Google Scholar
• Cazzola M, Pootrakul P, Huebers HA, et al. Erythroid marrow function in anemic patients. Blood 1987;69(1):296-301
   PubMed Web of Science ®Google Scholar
• Angelucci E, Barosi G, Camaschella C, et al. Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders. Haematologica 2008;93(5):741-52
   PubMed Web of Science ®Google Scholar
• Musallam KM, Angastiniotis M, Eleftheriou A, et al. Cross-talk between available guidelines for the management of patients with beta-thalassemia major. Acta Haematol 2013;130(2):64-73
   PubMed Web of Science ®Google Scholar
• Guidelines for the clinical management of thalassaemia, 2nd Revised Edition. Thalassaemia International Federation. 2008. Available from: http://www.thalassaemia.org.cy/wp-content/uploads/pdf/educational-programmes/Publications/Guidelines%20%282008%29/Thalassaemia%20Guidelines%20ENGLISH.pdf
   Google Scholar
• Standards of Care Guidelines for Thalassemia. Vichinsky E, Levine L. 2012. Available from: http://hemonc.cho.org/thalassemia/documents/SOCGuidelines2012.pdf
   Google Scholar
• Guidelines for the clinical care of patients with thalassemia in Canada. Thalassemia Foundation of Canada. 2009. Available from: http://www.thalassemia.ca/wp-content/uploads/Thalassemia-Guidelines_LR.pdf
   Google Scholar
• Standards for the clinical care of Children and adults with thalassaemia in the UK. United Kingdom Thalassaemia Society. 2008. Available from: http://sct.screening.nhs.uk/cms.php?folder=2493
   Google Scholar
• de Vries RR, Faber JC, Strengers PF. Haemovigilance: an effective tool for improving transfusion practice. Vox Sang 2011;100(1):60-7
   PubMedGoogle Scholar
• Olivieri NF, Muraca GM, O’Donnell A, et al. Studies in haemoglobin E beta-thalassaemia. Br J Haematol 2008;141(3):388-97
   PubMed Web of Science ®Google Scholar
• Premawardhena A, Fisher CA, Olivieri NF, et al. Haemoglobin E beta thalassaemia in Sri Lanka. Lancet 2005;366(9495):1467-70
   PubMed Web of Science ®Google Scholar
• Olivieri N. Treatment strategies for hemoglobin E beta-thalassemia. Blood Rev 2012;26(Suppl 1):S28-30
   PubMedGoogle Scholar
• Matteocci A, Pierelli L. Red blood cell alloimmunization in sickle cell disease and in thalassaemia: current status, future perspectives and potential role of molecular typing. Vox Sang 2013;106(3):197-208
   PubMedGoogle Scholar
• Chou ST, Liem RI, Thompson AA. Challenges of alloimmunization in patients with haemoglobinopathies. Br J Haematol 2012;159(4):394-404
   PubMed Web of Science ®Google Scholar
• Piga A, Serra M, Longo F, et al. Changing patterns of splenectomy in transfusion-dependent thalassemia patients. Am J Hematol 2011;86(9):808-10
   PubMed Web of Science ®Google Scholar
• Singer ST, Kuypers FA, Styles L, et al. Pulmonary hypertension in thalassemia: association with platelet activation and hypercoagulable state. Am J Hematol 2006;81(9):670-5
   PubMed Web of Science ®Google Scholar
• Vento S, Cainelli F, Cesario F. Infections and thalassaemia. Lancet Infect Dis 2006;6(4):226-33
   PubMedGoogle Scholar
• Rodeghiero F, Ruggeri M. Short- and long-term risks of splenectomy for benign haematological disorders: should we revisit the indications? Br J Haematol 2012;158(1):16-29
   PubMed Web of Science ®Google Scholar
• Cappellini MD, Robbiolo L, Bottasso BM, et al. Venous thromboembolism and hypercoagulability in splenectomized patients with thalassaemia intermedia. Br J Haematol 2000;111(2):467-73
   PubMed Web of Science ®Google Scholar
• Taher A, Isma’eel H, Mehio G, et al. Prevalence of thromboembolic events among 8,860 patients with thalassaemia major and intermedia in the Mediterranean area and Iran. Thromb Haemost 2006;96(4):488-91
   PubMed Web of Science ®Google Scholar
• Alexakis N, Dardamanis D, Albanopoulos K, et al. Incidence, risk factors, and outcome of portal vein thrombosis after laparoscopic-assisted splenectomy in beta-thalassemia patients: a prospective exploratory study. J Laparoendosc Adv Surg Tech A 2013;23(2):123-8
   PubMedGoogle Scholar
• Musallam KM, Taher AT, Cappellini MD, et al. Clinical experience with fetal hemoglobin induction therapy in patients with beta-thalassemia. Blood 2013;121(12):2199-212
   PubMed Web of Science ®Google Scholar
• Bradai M, Pissard S, Abad MT, et al. Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia. Transfusion 2007;47(10):1830-6
   PubMed Web of Science ®Google Scholar
• Mancuso A, Maggio A, Renda D, et al. Treatment with hydroxycarbamide for intermedia thalassaemia: decrease of efficacy in some patients during long-term follow up. Br J Haematol 2006;133(1):105-6
   PubMed Web of Science ®Google Scholar
• Rigano P, Pecoraro A, Calzolari R, et al. Desensitization to hydroxycarbamide following long-term treatment of thalassaemia intermedia as observed in vivo and in primary erythroid cultures from treated patients. Br J Haematol 2010;151(5):509-15
   PubMed Web of Science ®Google Scholar
• Taher AT, Musallam KM, Karimi M, et al. Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. Blood 2010;115(10):1886-92
   PubMed Web of Science ®Google Scholar
• Italia KY, Jijina FF, Merchant R, et al. Effect of hydroxyurea on the transfusion requirements in patients with severe HbE-beta-thalassaemia: a genotypic and phenotypic study. J Clin Pathol 2010;63(2):147-50
   PubMed Web of Science ®Google Scholar
• Singer ST, Kuypers FA, Olivieri NF, et al. Fetal haemoglobin augmentation in E/beta(0) thalassaemia: clinical and haematological outcome. Br J Haematol 2005;131(3):378-88
   PubMed Web of Science ®Google Scholar
• Thomas ED, Buckner CD, Sanders JE, et al. Marrow transplantation for thalassaemia. Lancet 1982;2(8292):227-9
   PubMed Web of Science ®Google Scholar
• Lucarelli G, Isgro A, Sodani P, et al. Hematopoietic stem cell transplantation in thalassemia and sickle cell anemia. Cold Spring Harb Perspect Med 2012;2(5):a011825
   PubMed Web of Science ®Google Scholar
• Lucarelli G, Gaziev J. Advances in the allogeneic transplantation for thalassemia. Blood Rev 2008;22(2):53-63
   PubMed Web of Science ®Google Scholar
• Lee SJ, Klein JP, Barrett AJ, et al. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood 2002;100(2):406-14
   PubMed Web of Science ®Google Scholar
• Flowers ME, Inamoto Y, Carpenter PA, et al. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood 2011;117(11):3214-19
   PubMed Web of Science ®Google Scholar
• Cesaro S, Pillon M, Talenti E, et al. A prospective survey on incidence, risk factors and therapy of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation. Haematologica 2005;90(10):1396-404
   PubMed Web of Science ®Google Scholar
• Angelucci E. Hematopoietic stem cell transplantation in thalassemia. Hematol Am Soc Hematol Educ Program 2010;2010:456-62
   PubMedGoogle Scholar
• Yannaki E, Karponi G, Zervou F, et al. Hematopoietic stem cell mobilization for gene therapy: superior mobilization by the combination of granulocyte-colony stimulating factor plus plerixafor in patients with beta-thalassemia major. Hum Gene Ther 2013;24(10):852-60
   PubMed Web of Science ®Google Scholar
• Cavazzana-Calvo M, Payen E, Negre O, et al. Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia. Nature 2010;467(7313):318-22
   PubMed Web of Science ®Google Scholar
• Rivella S. Ineffective erythropoiesis and thalassemias. Curr Opin Hematol 2009;16(3):187-94
   PubMed Web of Science ®Google Scholar
• Rivella S. The role of ineffective erythropoiesis in non-transfusion-dependent thalassemia. Blood Rev 2012;26(Suppl 1):S12-15
   PubMed Web of Science ®Google Scholar
• Suragani RNVS, Li R, Cawley S, et al. ACE-536 improves ineffective erythropoiesis, anemia and co-morbidities in beta-thalassemia. Blood 2012;120(21):abstract 248
   Google Scholar
• Cappellini MD, Porter J, Origa R, et al. A Phase 2a, open-label, dose-finding study to determine the safety and tolerability of sotatercept (ACE-011) in adults with beta-thalassemia: interim results. Blood 2013;122(21):abstract 3448
   Google Scholar
• Attie KM, Boyd IE, Wilson DM, et al. ACE-536 increases hemoglobin in healthy postmenopausal women: a Phase 1, randomized, double-blind, placebo-controlled, multiple ascending dose study. Blood 2013;122(21):abstract 3194
   Google Scholar
• Ginzburg Y, Rivella S. beta-thalassemia: a model for elucidating the dynamic regulation of ineffective erythropoiesis and iron metabolism. Blood 2011;118(16):4321-30
   PubMed Web of Science ®Google Scholar
• Zurlo MG, De Stefano P, Borgna-Pignatti C, et al. Survival and causes of death in thalassaemia major. Lancet 1989;2(8653):27-30
   PubMed Web of Science ®Google Scholar
• Chouliaras G, Berdoukas V, Ladis V, et al. Impact of magnetic resonance imaging on cardiac mortality in thalassemia major. J Magn Reson Imaging 2011;34(1):56-9
   PubMed Web of Science ®Google Scholar
• Voskaridou E, Ladis V, Kattamis A, et al. A national registry of haemoglobinopathies in Greece: deducted demographics, trends in mortality and affected births. Ann Hematol 2012;91(9):1451-8
   PubMed Web of Science ®Google Scholar
• Angelucci E, Brittenham GM, McLaren CE, et al. Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J Med 2000;343(5):327-31
   PubMed Web of Science ®Google Scholar
• Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 2006;107(9):3455-62
   PubMed Web of Science ®Google Scholar
• Olivieri NF, Brittenham GM, Matsui D, et al. Iron-chelation therapy with oral deferiprone in patients with thalassemia major. N Engl J Med 1995;332(14):918-22
   PubMed Web of Science ®Google Scholar
• Cappellini MD, Porter JB, El-Beshlawy A, et al. Tailoring iron chelation by iron intake and serum ferritin trends: the prospective multicenter EPIC study of deferasirox in 1744 patients with various transfusion-dependent anemias. Haematologica 2010;95(4):557-66
   PubMed Web of Science ®Google Scholar
• Musallam KM, Taher AT. Iron-chelating therapy for transfusional iron overload. N Engl J Med 2011;364(15):1476
   PubMed Web of Science ®Google Scholar
• Taher A, El Rassi F, Isma’eel H, et al. Correlation of liver iron concentration determined by R2 magnetic resonance imaging with serum ferritin in patients with thalassemia intermedia. Haematologica 2008;93(10):1584-6
   PubMed Web of Science ®Google Scholar
• Taher A, Porter J, Viprakasit V, et al. Serum ferritin for predicting clinically relevant LIC thresholds to guide management of patients with non-transfusion-dependent thalassemia treated with deferasirox: THALASSA study extension analysis. Haematologica 2013;98(Suppl 1):abstract S1171
   Google Scholar
• Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004;89(10):1187-93
   PubMed Web of Science ®Google Scholar
• Olivieri NF, Nathan DG, MacMillan JH, et al. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med 1994;331(9):574-8
   PubMed Web of Science ®Google Scholar
• Trachtenberg FL, Mednick L, Kwiatkowski JL, et al. Beliefs about chelation among thalassemia patients. Health Qual Life Outcomes 2012;10:148
   PubMed Web of Science ®Google Scholar
• Desferal® (deferoxamine) basic prescribing information. Novartis Pharmaceuticals. 2011. Available from: http://www.pharma.us.novartis.com/product/pi/pdf/desferal.pdf
   Google Scholar
• Pennell DJ, Berdoukas V, Karagiorga M, et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood 2006;107(9):3738-44
   PubMed Web of Science ®Google Scholar
• Pennell DJ, Porter JB, Piga A, et al. Deferasirox compared with deferoxamine for the removal of cardiac iron in patients with beta-thalassemia major: 2-year data from the CORDELIA extension. Blood 2013;122(21):abstract 1018
   Google Scholar
• Pennell DJ, Udelson JE, Arai AE, et al. Cardiovascular function and treatment in beta-thalassemia major: a consensus statement from the American Heart Association. Circulation 2013;128(3):281-308
   PubMed Web of Science ®Google Scholar
• Cossu P, Toccafondi C, Vardeu F, et al. Iron overload and desferrioxamine chelation therapy in beta-thalassemia intermedia. Eur J Pediatr 1981;137(3):267-71
   PubMed Web of Science ®Google Scholar
• Brill PW, Winchester P, Giardina PJ, et al. Deferoxamine-induced bone dysplasia in patients with thalassemia major. AJR Am J Roentgenol 1991;156(3):561-5
   PubMed Web of Science ®Google Scholar
• Nichols-Vinueza DX, White MT, Powell AJ, et al. MRI-guided iron assessment and oral chelator use improve iron status in thalassemia major patients: A six-year single center retrospective cohort study. Blood 2013;122(21):abstract 563
   Google Scholar
• Ferriprox summary of product characteristics. Apotex. 2011. Available from: http://www.emea.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000236/WC500022050.pdf
   Google Scholar
• Tanner MA, Galanello R, Dessi C, et al. Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. J Cardiovasc Magn Reson 2008;10:12
   PubMed Web of Science ®Google Scholar
• Olivieri NF, Koren G, Matsui D, et al. Reduction of tissue iron stores and normalization of serum ferritin during treatment with the oral iron chelator L1 in thalassemia intermedia. Blood 1992;79(10):2741-8
   PubMed Web of Science ®Google Scholar
• Rombos Y, Tzanetea R, Konstantopoulos K, et al. Chelation therapy in patients with thalassemia using the orally active iron chelator deferiprone (L1). Haematologica 2000;85(2):115-17
   PubMed Web of Science ®Google Scholar
• Akrawinthawong K, Chaowalit N, Chatuparisuth T, et al. Effectiveness of deferiprone in transfusion-independent beta-thalassemia/HbE patients. Hematology (Am Soc Hematol Educ Program) 2011;16(2):113-22
   Google Scholar
• Ceci A, Baiardi P, Felisi M, et al. The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. Br J Haematol 2002;118(1):330-6
   PubMed Web of Science ®Google Scholar
• Cohen AR, Galanello R, Piga A, et al. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood 2003;102(5):1583-7
   PubMed Web of Science ®Google Scholar
• Hoffbrand AV, Cohen A, Hershko C. Role of deferiprone in chelation therapy for transfusional iron overload. Blood 2003;102(1):17-24
   PubMed Web of Science ®Google Scholar
• Deugnier Y, Turlin B, Ropert M, et al. Improvement in liver pathology of patients with beta-thalassemia treated with deferasirox for at least 3 years. Gastroenterology 2011;141(4):1202-11
   PubMed Web of Science ®Google Scholar
• Aydinok Y, Kattamis A, Cappellini MD, et al. Deferasirox–deferoxamine combination therapy reduces cardiac iron with rapid liver iron removal in patients with severe transfusional iron overload (HYPERION). Blood 2013;122(21):abstract 2257
   Google Scholar
• EXJADE® (deferasirox) US Prescribing Information. Novartis Pharmaceuticals. 2013. Available from: http://www.pharma.us.novartis.com/product/pi/pdf/exjade.pdf
   Google Scholar
• Taher AT, Porter JB, Viprakasit V, et al. Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study. Ann Hematol 2013;92(11):1485-93
   PubMed Web of Science ®Google Scholar
• Taher AT, Porter J, Viprakasit V, et al. Deferasirox significantly reduces iron overload in non-transfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study. Blood 2012;120(5):970-7
   PubMed Web of Science ®Google Scholar
• Taher A, Porter J, Viprakasit V, et al. The safety profile of deferasirox remains consistent as non-transfusion-dependent thalassemia patients approach the target liver iron concentration of <3 mg Fe/g dw for interrupting chelation. Haematologica 2013;98(Suppl 1):abstract P391
   Google Scholar
• Grange S, Bertrand DM, Guerrot D, et al. Acute renal failure and Fanconi syndrome due to deferasirox. Nephrol Dial Transplant 2010;25(7):2376-8
   PubMed Web of Science ®Google Scholar
• Yew CT, Talaulikar GS, Falk MC, et al. Acute interstitial nephritis secondary to deferasirox causing acute renal injury needing short-term dialysis. Nephrology (Carlton) 2010;15(3):377
   PubMedGoogle Scholar
• Mokhtar GM, Gadallah M, El Sherif NH, et al. Morbidities and mortality in transfusion-dependent Beta-thalassemia patients (single-center experience). Pediatr Hematol Oncol 2013;30(2):93-103
   PubMed Web of Science ®Google Scholar
• Boelaert JR, de Locht M, Van Cutsem J, et al. Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies. J Clin Invest 1993;91(5):1979-86
   PubMed Web of Science ®Google Scholar
• Cunningham MJ, Macklin EA, Neufeld EJ, et al. Complications of beta-thalassemia major in North America. Blood 2004;104(1):34-9
   PubMed Web of Science ®Google Scholar
• Mallat ME, Sharara AI. Treatment and prevention of hepatitis B and C in thalassemia. Hemoglobin 2009;33(Suppl 1):S139-44
   Google Scholar
• Modell B, Khan M, Darlison M, et al. Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2008;10:42
   PubMed Web of Science ®Google Scholar
• Sadelain M. Recent advances in globin gene transfer for the treatment of beta-thalassemia and sickle cell anemia. Curr Opin Hematol 2006;13(3):142-8
   PubMed Web of Science ®Google Scholar
• A study evaluating the safety and efficacy of the LentiGlobin® BB305 drug product in beta-thalassemia major subjects. NCT01745120. 2013. Available from: http://www.clinicaltrials.gov/show/NCT01745120
   Google Scholar
• Beta-thalassemia product development. Bluebirdbio. 2014. Available from: http://www.bluebirdbio.com/product-thalassemia.php
   Google Scholar
• Learn about the Northstar Study. Bluebirdbio. 2014. Available from: http://northstarstudy.com/
   Google Scholar
• Taher AT, Musallam KM, Karimi M, et al. Contemporary approaches to treatment of beta-thalassemia intermedia. Blood Rev 2012;26(Suppl 1):S24-7
   PubMed Web of Science ®Google Scholar
• Lobo C, Angulo IL, Aparicio LR, et al. Retrospective epidemiological study of Latin American patients with transfusional hemosiderosis: the first Latin American epidemiological study in iron overload–the RELATH study. Hematology (Am Soc Hematol Educ Program) 2011;16(5):265-73
   Google Scholar
• Maakaron JE, Cappellini MD, Graziadei G, et al. Hepatocellular carcinoma in hepatitis-negative patients with thalassemia intermedia: a closer look at the role of siderosis. Ann Hepatol 2013;12(1):142-6
   PubMed Web of Science ®Google Scholar
• European Association of the Study of the Liver. 2011 European Association of the Study of the Liver hepatitis C virus clinical practice guidelines. Liver Int 2012;32(Suppl 1):2-8
   Google Scholar
• Ramachandran P, Fraser A, Agarwal K, et al. UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients. Aliment Pharmacol Ther 2012;35(6):647-62
   PubMed Web of Science ®Google Scholar
• Wanachiwanawin W. Infections in E-beta thalassemia. J Pediatr Hematol Oncol 2000;22(6):581-7
   PubMedGoogle Scholar
• Borgna-Pignatti C, Carnelli V, Caruso V, et al. Thromboembolic events in beta thalassemia major: an Italian multicenter study. Acta Haematol 1998;99(2):76-9
   PubMedGoogle Scholar
• Taher AT, Musallam KM, Karimi M, et al. Splenectomy and thrombosis: the case of thalassemia intermedia. J Thromb Haemost 2010;8(10):2152-8
   PubMed Web of Science ®Google Scholar
• Karimi M, Khanlari M, Rachmilewitz EA. Cerebrovascular accident in beta-thalassemia major (beta-TM) and beta-thalassemia intermedia (beta-TI). Am J Hematol 2008;83(1):77-9
   PubMed Web of Science ®Google Scholar
• Succar J, Musallam KM, Taher AT. Thalassemia and venous thromboembolism. Mediterr J Hematol Infect Dis 2011;3(1):e2011025
   PubMedGoogle Scholar
• Taher A, Isma’eel H, Cappellini MD. Thalassemia intermedia: revisited. Blood Cells Mol Dis 2006;37(1):12-20
   PubMed Web of Science ®Google Scholar
• Borgna-Pignatti C, Gamberini MR. Complications of thalassemia major and their treatment. Expert Rev Hematol 2011;4(3):353-66
   PubMed Web of Science ®Google Scholar
• Dore F, Cianciulli P, Rovasio S, et al. Incidence and clinical study of ectopic erythropoiesis in adult patients with thalassemia intermedia. Ann Ital Med Int 1992;7(3):137-40
   PubMedGoogle Scholar
• Shin KH, Sharma S, Gregoritch SJ, et al. Combined radiotherapeutic and surgical management of a spinal cord compression by extramedullary hematopoiesis in a patient with hemoglobin E beta-thalassemia. Acta Haematol 1994;91(3):154-7
   PubMedGoogle Scholar
• Haidar R, Mhaidli H, Taher AT. Paraspinal extramedullary hematopoiesis in patients with thalassemia intermedia. Eur Spine J 2010;19(6):871-8
   PubMed Web of Science ®Google Scholar
• Origa R, Fiumana E, Gamberini MR, et al. Osteoporosis in beta-thalassemia: Clinical and genetic aspects. Ann NY Acad Sci 2005;1054:451-6
   PubMed Web of Science ®Google Scholar
• National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979;28(12):1039-57
   PubMed Web of Science ®Google Scholar
• Kosaryan M, Mahdavi MR, Aliasgharian A, et al. Credibility of measurement of fructosamine and hemoglobin A1C in estimating blood glucose level of diabetic patients with thalassemia major. Open J Hematol 2012;3(4):1-7
   Google Scholar
• Farmaki K, Angelopoulos N, Anagnostopoulos G, et al. Effect of enhanced iron chelation therapy on glucose metabolism in patients with beta-thalassaemia major. Br J Haematol 2006;134(4):438-44
   PubMed Web of Science ®Google Scholar
• Mangiagli A, Campisi S, De Sanctis V, et al. Effects of acarbose in beta-thalassaemia major patients with normal glucose tolerance and hyperinsulinism. Pediatr Endocrinol Rev 2004;2(Suppl 2):272-5
   PubMedGoogle Scholar
• Fernandes JL, Fabron A Jr, Verissimo M. Early cardiac iron overload in children with transfusion-dependent anemias. Haematologica 2009;94(12):1776-7
   PubMedGoogle Scholar
• Musallam KM, Rivella S, Vichinsky E, et al. Non-transfusion-dependent thalassemias. Haematologica 2013;98(6):833-44
   PubMed Web of Science ®Google Scholar